Bio-Works Technologies AB Cash Flow Conversion Efficiency

Latest as of December 2025: -0.085x

Bio-Works Technologies AB cash flow conversion efficiency. Based on the latest financial reports, Bio-Works Technologies AB (BIOWKS) has a cash flow conversion efficiency ratio of -0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.17 Million ≈ $-449.08K USD) by net assets (Skr49.21 Million ≈ $5.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Bio-Works Technologies AB (2015–2025)

Cash flow conversion efficiency of Bio-Works Technologies AB from 2015 to 2025. This chart illustrates how Bio-Works Technologies AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIOWKS live share price for real-time trading data and today's change.

Bio-Works Technologies AB Cash Flow Conversion Ratio Explained

Bio-Works Technologies AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Bio-Works Technologies AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bio-Works Technologies AB ranked by their cash flow conversion efficiency. Also see Bio-Works Technologies AB stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Shaftesbury Capital PLC LSE:SHC	0.002x
Li Kang Biomedical Co Ltd TWO:6242	-0.004x
Hastings Technology Metals Ltd AU:HAS	-0.035x
Communication & System Solution Public Company Limited BK:CSS	0.010x
Cipherlab Co Ltd TWO:6160	-0.064x
EVZ Ltd AU:EVZ	0.060x
Tinka Resources Limited V:TK	-0.005x
Eurospan Holdings Bhd KLSE:7094	0.002x

Annual Cash Flow Conversion Efficiency for Bio-Works Technologies AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of Bio-Works Technologies AB from 2015 to 2025. Review Bio-Works Technologies AB free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr49.21 Million ≈ $5.30 Million	Skr-18.81 Million ≈ $-2.02 Million	-0.382x	+60.52%
2024-12-31	Skr44.58 Million ≈ $4.80 Million	Skr-43.17 Million ≈ $-4.65 Million	-0.968x	+27.73%
2023-12-31	Skr44.03 Million ≈ $4.74 Million	Skr-58.99 Million ≈ $-6.35 Million	-1.340x	-127.40%
2022-12-31	Skr67.69 Million ≈ $7.28 Million	Skr-39.88 Million ≈ $-4.29 Million	-0.589x	-378.17%
2021-12-31	Skr108.51 Million ≈ $11.68 Million	Skr-13.37 Million ≈ $-1.44 Million	-0.123x	+89.36%
2020-12-31	Skr37.46 Million ≈ $4.03 Million	Skr-43.36 Million ≈ $-4.67 Million	-1.158x	-137.44%
2019-12-31	Skr82.13 Million ≈ $8.84 Million	Skr-40.04 Million ≈ $-4.31 Million	-0.488x	+13.37%
2018-12-31	Skr61.64 Million ≈ $6.63 Million	Skr-34.69 Million ≈ $-3.73 Million	-0.563x	-163.23%
2017-12-31	Skr99.32 Million ≈ $10.69 Million	Skr-21.23 Million ≈ $-2.28 Million	-0.214x	+65.04%
2016-12-31	Skr23.64 Million ≈ $2.54 Million	Skr-14.46 Million ≈ $-1.56 Million	-0.612x	-4.42%
2015-12-31	Skr22.41 Million ≈ $2.41 Million	Skr-13.12 Million ≈ $-1.41 Million	-0.586x	--

About Bio-Works Technologies AB

ST:BIOWKS Sweden Medical Instruments & Supplies

Market Cap

$32.93 Million

Skr306.03 Million SEK

Market Cap Rank

#23234 Global

#437 in Sweden

Share Price

Skr3.06

Change (1 day)

-7.27%

52-Week Range

Skr2.21 - Skr4.68

All Time High

Skr28.60